中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2013年
26期
2025-2028
,共4页
顾长江%吴寒%盛陈毅%倪启超
顧長江%吳寒%盛陳毅%倪啟超
고장강%오한%성진의%예계초
半乳凝素-9%肝细胞肝癌%预后%肿瘤糖基化
半乳凝素-9%肝細胞肝癌%預後%腫瘤糖基化
반유응소-9%간세포간암%예후%종류당기화
Galectin-9%Hepatocellular carcinoma%Prognosis%Tumor glycosylation
目的 探讨半乳凝素(galectin)-9在肝细胞肝癌(HCC)患者中的表达及与肿瘤预后的关系.方法 应用免疫组织化学方法检测包含147例HCC患者的组织芯片中galectin-9的表达,观察其与临床病理特征和肿瘤预后的关系.采用ELISA法检测HCC患者(n=31)、肝硬化患者(n=12)及健康对照组(n=12)血浆中galectin-9的水平,并进行比较分析.结果 galectin-9表达于肿瘤细胞的胞膜、胞质、细胞核和肿瘤间质中.所有病例肿瘤间质均有galectin-9的表达,而约11.5％(17/147)病例的肝癌细胞不表达,HCC组织中galectin-9水平较健康对照组和肝硬化组明显下调,低表达galectin-9的HCC患者预后显著差于高表达组患者(P＜0.05).而HCC组血浆galectin-9浓度为(8.36±2.12) μg/L,较健康对照组[(4.62±1.59)μg/L]及肝硬化组[(5.11±1.92) μg/L]明显增高(P＜0.05).多因素分析表明galectin-9是HCC预后的一项独立预测因子.结论 galectin-9是HCC术后复发与转移的一项独立预测指标,有可能成为HCC判断预后的标志物以及治疗的潜在靶点.
目的 探討半乳凝素(galectin)-9在肝細胞肝癌(HCC)患者中的錶達及與腫瘤預後的關繫.方法 應用免疫組織化學方法檢測包含147例HCC患者的組織芯片中galectin-9的錶達,觀察其與臨床病理特徵和腫瘤預後的關繫.採用ELISA法檢測HCC患者(n=31)、肝硬化患者(n=12)及健康對照組(n=12)血漿中galectin-9的水平,併進行比較分析.結果 galectin-9錶達于腫瘤細胞的胞膜、胞質、細胞覈和腫瘤間質中.所有病例腫瘤間質均有galectin-9的錶達,而約11.5％(17/147)病例的肝癌細胞不錶達,HCC組織中galectin-9水平較健康對照組和肝硬化組明顯下調,低錶達galectin-9的HCC患者預後顯著差于高錶達組患者(P＜0.05).而HCC組血漿galectin-9濃度為(8.36±2.12) μg/L,較健康對照組[(4.62±1.59)μg/L]及肝硬化組[(5.11±1.92) μg/L]明顯增高(P＜0.05).多因素分析錶明galectin-9是HCC預後的一項獨立預測因子.結論 galectin-9是HCC術後複髮與轉移的一項獨立預測指標,有可能成為HCC判斷預後的標誌物以及治療的潛在靶點.
목적 탐토반유응소(galectin)-9재간세포간암(HCC)환자중적표체급여종류예후적관계.방법 응용면역조직화학방법검측포함147례HCC환자적조직심편중galectin-9적표체,관찰기여림상병리특정화종류예후적관계.채용ELISA법검측HCC환자(n=31)、간경화환자(n=12)급건강대조조(n=12)혈장중galectin-9적수평,병진행비교분석.결과 galectin-9표체우종류세포적포막、포질、세포핵화종류간질중.소유병례종류간질균유galectin-9적표체,이약11.5％(17/147)병례적간암세포불표체,HCC조직중galectin-9수평교건강대조조화간경화조명현하조,저표체galectin-9적HCC환자예후현저차우고표체조환자(P＜0.05).이HCC조혈장galectin-9농도위(8.36±2.12) μg/L,교건강대조조[(4.62±1.59)μg/L]급간경화조[(5.11±1.92) μg/L]명현증고(P＜0.05).다인소분석표명galectin-9시HCC예후적일항독립예측인자.결론 galectin-9시HCC술후복발여전이적일항독립예측지표,유가능성위HCC판단예후적표지물이급치료적잠재파점.
Objective To explore the prognostic value of galectin-9 in patients with hepatocellular carcinoma (HCC).Methods Galectin-9 was validated by immunohistochemisty in tissue microarrays from HCC patients (n =147) and statistically assessed for the prognosis.The serum levels of galectin-9 from another independent cohort including HCC patients (n =31) were assessed by enzyme-linked immunosorbent assay (ELISA).Results Patients with a lower expression of galectin-9 had significantly worse prognosis than those with a higher expression.The serum level of galectin-9 of HCC patients (8.36 ± 2.12) μg/L was significantly lower than that in healthy (4.62 ± 1.59) μg/L and liver cirrhosis controls (5.11 ± 1.92) μg/L (P ＜ 0.05).Multivariate Cox proportional hazard analysis showed that galectin-9 was an independent marker for predicting a poor prognosis of HCC patients.Conclusion Involved in the poor prognosis of HCC patients,galectin-9 may be a new predictor of recurrence for HCC patients and serve as a high-priority therapeutic target.
